Cancer Family
Lung Neoplasm
CI-CAN-00000221Explore in graph →
Non-malignant2,726 active trials51 approved drugs619 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000221Explore in graph →
Clinical trials
11,603 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03686007 | Multimedia Self-Management Intervention for Lung Cancer Surgery Family Caregivers and Patients | active not recruiting | N/A | 380 | City of Hope Medical CenterOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04258813 | Onco-primary Care Networking to Support TEAM-based Care(ONE TEAM) | active not recruiting | N/A | 313 | Duke UniversityOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT02422381 | MK-3475 and Gemcitabine in Non-Small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 16 | Providence Health & ServicesOTHER | 1 | Feb 18, 2026 | clinicaltrials |
| NCT05721950 | A Study to Learn About Brigatinib Treatment Information Available in Chinese Participants With Non-Small-cell Lung Cancer (NSCLC)(Brilliant) | active not recruiting | — | 154 | TakedaINDUSTRY | 1 | Feb 18, 2026 | clinicaltrials |
| NCT03767348 | Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)(IGNYTE) | active not recruiting | Phase 2 | 340 | Replimune, Inc.INDUSTRY | 5 | Feb 13, 2026 | clinicaltrials |
| NCT06445192 | Evaluating the Impact of a Virtually Supervised Exercise Intervention and Group Counseling on Inflammation and the Microbiome of Smokers at High Risk for Lung Cancer, BE FIT Trial | active not recruiting | N/A | 65 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2026 | clinicaltrials |
| NCT03830918 | Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy | active not recruiting | Phase 1 / Phase 2 | 59 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05714891 | Neoadjuvant Platform Trial in Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 4 | Canadian Cancer Trials GroupNETWORK | 1 | Feb 12, 2026 | clinicaltrials |
| NCT05239143 | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 180 | Poseida Therapeutics, Inc.INDUSTRY | 1 | Feb 9, 2026 | clinicaltrials |
| NCT07312682 | Application of 4DCT-Based Pulmonary Ventilation Imaging in Lung Cancer Radiotherapy(FLAR-4DCT) | active not recruiting | — | 202 | The Second Affiliated Hospital of Chongqing Medical UniversityOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT02152631 | A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer(JUNIPER) | active not recruiting | Phase 3 | 453 | Eli Lilly and CompanyINDUSTRY | 21 | Feb 6, 2026 | clinicaltrials |
| NCT02514512 | Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking(LIGHTSABR) | active not recruiting | N/A | 20 | Royal North Shore HospitalOTHER | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04395677 | A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene | active not recruiting | Phase 2 | 173 | Nuvation Bio Inc.INDUSTRY | 1 | Feb 6, 2026 | clinicaltrials |
| NCT04884282 | Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)(COMBI-TED) | active not recruiting | Phase 2 | 105 | Fondazione Ricerca TraslazionaleOTHER | 3 | Feb 6, 2026 | clinicaltrials |
| NCT02732834 | Clinician-Patient Communication in Lung Cancer Care | active not recruiting | — | 294 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT07389642 | Brain Oligometastasis in NSCLC(OligoLung) | active not recruiting | — | 46 | University Hospital, BordeauxOTHER | 1 | Feb 5, 2026 | clinicaltrials |
| NCT03808662 | Randomized Study of Stereotactic Body Radiation Therapy (SBRT) in Patients With Oligoprogressive Metastatic Cancers of the Breast and Lung | active not recruiting | Phase 2 | 107 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Feb 4, 2026 | clinicaltrials |
| NCT04223596 | Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients(CUBIK) | active not recruiting | Phase 2 | 33 | Fundación GECPOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT05786625 | Bronchoscopic Microwave Ablation of Lung Tissue(AB1MALT) | active not recruiting | — | 35 | Creo Medical LimitedINDUSTRY | 2 | Feb 2, 2026 | clinicaltrials |
| NCT05502237 | Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer(STAR-121) | active not recruiting | Phase 3 | 1,021 | Gilead SciencesINDUSTRY | 23 | Jan 30, 2026 | clinicaltrials |
| NCT06984588 | A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1- and CD73- Selected Non-Small Cell Lung Cancer | active not recruiting | Phase 2 / Phase 3 | 450 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT07005336 | A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 150 | TJ Biopharma Co., Ltd.INDUSTRY | 1 | Jan 30, 2026 | clinicaltrials |
| NCT03474497 | UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade | active not recruiting | Phase 1 / Phase 2 | 18 | Megan Daly, MDOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT03974022 | Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) | active not recruiting | Phase 1 / Phase 2 | 315 | Dizal PharmaceuticalsINDUSTRY | 13 | Jan 29, 2026 | clinicaltrials |
| NCT04310891 | Markerless Image Guidance Using Intrafraction Kolovoltage X-ray Imaging for Lung Cancer Radiotherapy(VALKIM) | active not recruiting | — | 5 | Royal North Shore HospitalOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT05340309 | Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 5 | University of Southern CaliforniaOTHER | 1 | Jan 29, 2026 | clinicaltrials |
| NCT02432963 | Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | active not recruiting | Phase 1 | 11 | City of Hope Medical CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT03824327 | Papaverine and Stereotactic Body Radiotherapy (SBRT) for Non Small Cell Lung Cancer (NSCLC) or Lung Metastases | active not recruiting | Phase 1 | 19 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT04432142 | Immune Profiling of Stage III Non-small Cell Lung Cancer Patients Treated With Concurrent Chemoradiation and Adjuvant Durvalumab: A Prospective Observational Phase II Trial(IPON-1) | active not recruiting | — | 45 | Maastricht Radiation OncologyOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05206812 | Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | active not recruiting | Phase 2 | 25 | Yonsei UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05786430 | Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib(LUCAS) | active not recruiting | Phase 2 | 87 | Yonsei UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05816252 | A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | active not recruiting | Phase 2 | 356 | Klus Pharma Inc.INDUSTRY | 6 | Jan 27, 2026 | clinicaltrials |
| NCT06487156 | A Study to Evaluate First-line Ipilimumab + Nivolumab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer(FINN) | active not recruiting | — | 404 | Bristol-Myers SquibbINDUSTRY | 1 | Jan 27, 2026 | clinicaltrials |
| NCT02779751 | A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer | active not recruiting | Phase 1 | 100 | Eli Lilly and CompanyINDUSTRY | 7 | Jan 26, 2026 | clinicaltrials |
| NCT05560776 | Optimizing Endobronchial Ultrasound Sampling for Molecular Markers for NSCLC(OPTIMAL) | active not recruiting | N/A | 120 | Institut universitaire de cardiologie et de pneumologie de Québec, University LavalOTHER | 1 | Jan 26, 2026 | clinicaltrials |
| NCT03891953 | Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. | active not recruiting | Phase 1 | 98 | Novartis PharmaceuticalsINDUSTRY | 6 | Jan 21, 2026 | clinicaltrials |
| NCT05601973 | Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI(AMAZE-lung) | active not recruiting | Phase 2 | 60 | ETOP IBCSG Partners FoundationNETWORK | 6 | Jan 21, 2026 | clinicaltrials |
| NCT05708599 | A Study to Compare Tissue and Liquid Biopsies in People With Different Types of Cancer | active not recruiting | N/A | 102 | Boehringer IngelheimINDUSTRY | 1 | Jan 21, 2026 | clinicaltrials |
| NCT04743505 | Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 27 | Washington University School of MedicineOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05740943 | Induction Lorlatinib in Stage III Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 48 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT02411448 | A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)(RELAY) | active not recruiting | Phase 3 | 545 | Eli Lilly and CompanyINDUSTRY | 14 | Jan 16, 2026 | clinicaltrials |
| NCT06879717 | A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients(PULMO-01) | active not recruiting | Phase 1 / Phase 2 | 45 | iOncturaINDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05089916 | Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study(ROSE) | active not recruiting | Phase 2 | 42 | AIO-Studien-gGmbHOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05353257 | A Study to Evaluate the Efficacy and Safety of Serplulimab in Combination With Chemotherapy and Concurrent Radiotherapy in Patients With Limited-Stage Small Cell Lung Cancer | active not recruiting | Phase 3 | 511 | Shanghai Henlius BiotechINDUSTRY | 11 | Jan 13, 2026 | clinicaltrials |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients(RAMP203) | active not recruiting | Phase 1 / Phase 2 | 153 | Verastem, Inc.INDUSTRY | 6 | Jan 12, 2026 | clinicaltrials |
| NCT05346185 | Lung Cancer Surgery in Sarcopenia Patients With Old Age(LUCAS-PEN) | active not recruiting | — | 400 | Seoul National University HospitalOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT05902520 | Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors(ACT) | active not recruiting | Phase 1 | 18 | AgonOx, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT04919811 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC(TRUST-II) | active not recruiting | Phase 2 | 217 | Nuvation Bio Inc.INDUSTRY | 9 | Jan 7, 2026 | clinicaltrials |
| NCT05544929 | A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers | active not recruiting | Phase 1 | 126 | Novartis PharmaceuticalsINDUSTRY | 12 | Jan 6, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Feb 20, 2026source: clinicaltrials